Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis
about
Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos inHepatitis C: New challenges in liver transplantationEffectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care settingFinal Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis.Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection.Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment.Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1.Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir.Commentary: treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals - authors' reply.The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.
P2860
Q26820811-C6F105C3-0D4E-4D06-8CFB-E5582279C1AFQ26999368-782F6583-178E-40C4-94B0-D169264CBF58Q34543615-7BD5ACF4-D555-402E-9EE6-DDCD93356A8BQ35785198-0ED957C9-6EEF-4884-88B2-FC16B72C3CD1Q35790393-7D03F218-E3BD-4980-B950-8E4FA2F5AF4EQ35928048-A568E002-66E5-471E-BF98-C511BC890726Q38249065-BEB7B492-2211-427A-8679-BFB9D932C9B1Q38515906-9906D0C8-DCA5-45CB-B999-8541F7688FECQ38790455-1CC43202-7BA5-4099-99D3-BE089D4228E1Q39067369-C04E2EE3-B24D-4D4D-B6CF-F31446F26651Q40629289-A503EF65-DA81-4EFC-A9D3-26FD38E74C0BQ43223289-E2386863-18F2-4791-84D1-E9DDB565A5D4Q46120202-B0F64AA7-C452-408D-871C-8067A116D3F7Q52656603-2C8B4814-9D72-4956-A522-FF31E2C437D1Q55423430-174A8AB7-E637-49D1-86D1-1D27EAD228EF
P2860
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Telaprevir or boceprevir tripl ...... varying severity of cirrhosis
@ast
Telaprevir or boceprevir tripl ...... varying severity of cirrhosis
@en
type
label
Telaprevir or boceprevir tripl ...... varying severity of cirrhosis
@ast
Telaprevir or boceprevir tripl ...... varying severity of cirrhosis
@en
prefLabel
Telaprevir or boceprevir tripl ...... varying severity of cirrhosis
@ast
Telaprevir or boceprevir tripl ...... varying severity of cirrhosis
@en
P2093
P2860
P356
P1476
Telaprevir or boceprevir tripl ...... varying severity of cirrhosis
@en
P2093
N A Terrault
R C Murphy
V A Shvachko
P2860
P304
P356
10.1111/APT.12718
P407
P577
2014-03-24T00:00:00Z